MbrlCatalogueTitleDetail

Do you wish to reserve the book?
POS0822 ASSOCIATION BETWEEN NAILFOLD CAPILLAROSCOPIC PATTERN AND INCIDENT INTERSTITIAL LUNG DISEASE IN SYSTEMIC SCLEROSIS: A EUSTAR DATABASE ANALYSIS
POS0822 ASSOCIATION BETWEEN NAILFOLD CAPILLAROSCOPIC PATTERN AND INCIDENT INTERSTITIAL LUNG DISEASE IN SYSTEMIC SCLEROSIS: A EUSTAR DATABASE ANALYSIS
Hey, we have placed the reservation for you!
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
You are currently in the queue to collect this book. You will be notified once it is your turn to collect the book.
Oops! Something went wrong.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
POS0822 ASSOCIATION BETWEEN NAILFOLD CAPILLAROSCOPIC PATTERN AND INCIDENT INTERSTITIAL LUNG DISEASE IN SYSTEMIC SCLEROSIS: A EUSTAR DATABASE ANALYSIS
Oops! Something went wrong.
Oops! Something went wrong.
While trying to remove the title from your shelf something went wrong :( Kindly try again later!
Title added to your shelf!
Title added to your shelf!
View what I already have on My Shelf.
Oops! Something went wrong.
Oops! Something went wrong.
While trying to add the title to your shelf something went wrong :( Kindly try again later!
Do you wish to request the book?
POS0822 ASSOCIATION BETWEEN NAILFOLD CAPILLAROSCOPIC PATTERN AND INCIDENT INTERSTITIAL LUNG DISEASE IN SYSTEMIC SCLEROSIS: A EUSTAR DATABASE ANALYSIS
POS0822 ASSOCIATION BETWEEN NAILFOLD CAPILLAROSCOPIC PATTERN AND INCIDENT INTERSTITIAL LUNG DISEASE IN SYSTEMIC SCLEROSIS: A EUSTAR DATABASE ANALYSIS

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
How would you like to get it?
We have requested the book for you! Sorry the robot delivery is not available at the moment
We have requested the book for you!
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
POS0822 ASSOCIATION BETWEEN NAILFOLD CAPILLAROSCOPIC PATTERN AND INCIDENT INTERSTITIAL LUNG DISEASE IN SYSTEMIC SCLEROSIS: A EUSTAR DATABASE ANALYSIS
POS0822 ASSOCIATION BETWEEN NAILFOLD CAPILLAROSCOPIC PATTERN AND INCIDENT INTERSTITIAL LUNG DISEASE IN SYSTEMIC SCLEROSIS: A EUSTAR DATABASE ANALYSIS
Journal Article

POS0822 ASSOCIATION BETWEEN NAILFOLD CAPILLAROSCOPIC PATTERN AND INCIDENT INTERSTITIAL LUNG DISEASE IN SYSTEMIC SCLEROSIS: A EUSTAR DATABASE ANALYSIS

2024
Request Book From Autostore and Choose the Collection Method
Overview
Background:In systemic sclerosis interstitial lung disease (ILD) is the leading cause of mortality [1]. An important unmet clinical need is the to identify patients at risk to develop ILD early, in order to implement personalized monitoring strategies. Although no predictive algorithm is yet available in clinical care, nailfold capillaroscopy is emerging as a promising candidate biomarker to predict the onset of ILD [2].Objectives:The objective of this study was to evaluate the association between transitions in nailfold capillaroscopy patterns and incident ILD.Methods:Patient data from the EUSTAR database were collected of those patients who had least one ILD-free visit with a documented scleroderma pattern at nailfold capillaroscopy, spanning up to 5 years. The baseline for analysis was established as the first recorded ILD-free visit with a documented scleroderma pattern. Only data of patients fulfilling the following key criteria were included in the analysis: age ≥ 18 years, fulfilling ACR-EULAR classification criteria, disease duration from first non-Raynaud phenomenon ≤ 5 years, HRCT confirmed absence of ILD at baseline, at least one follow-up nailfold capillaroscopy, and a minimal follow-up duration of1 year.Mixed logistic regression models were constructed to assess the association between annual risk of ILD and nailfold capillaroscopy pattern. The model was corrected for a priori defined confounders, namely gender, diffuse cutaneous subtype, Caucasian ethnicity, presence of anti-topoisomerase-I antibodies, presence of anti-RNA polymerase III antibodies, higher age, forced vital capacity % predicted, and diffusing capacity of the lungs for carbon monoxide % predicted. In addition, the other covariates were assessed for confounding with a change-in-estimation model.Results:We identified 275 patients meeting the eligibility criteria, from which 90(33%) patients had an early scleroderma pattern, 135(49%) patients had an active scleroderma pattern, and 50(18%) patients had a late scleroderma pattern. Patients with a more severe nailfold capillaroscopic pattern (i.e. active or late) had an unfavourable disease phenotype (Table 1).In our cohort, 66(24%) of the patients developed ILD after a mean(SD) follow-up period of 2.2(1.2) years. The mixed regression model corrected for the a priori defined confounders as well as for modified Rodnan skin score revealed a rise in the annual risk for incident ILD with worsening severity of nailfold capillaroscopic pattern: OR(95%CI); 3.76(1.99-7.11, p<0.01 (Figure 1). Thus, these results indicate an increased risk for incident ILD after? a transition towards a deteriorating nailfold capillaroscopic pattern, along with a reduced risk for incident ILD when transitioning to an improved nailfold capillaroscopic pattern.Conclusion:In conclusion progression towards a more severe nailfold capillaroscopic pattern is associated with a higher risk to develop ILD, necessitating longitudinal nailfold capillaroscopic assessments to identify patients at risk in the early disease stage.REFERENCES:[1] Elhai M et al., Ann Rheum Dis. 2017;76(11):1897-905.[2] Smith V et al., Autoimmun Rev. 2020;19(9):102619.Acknowledgements:NIL.Disclosure of Interests:Arthiha Velauthapillai: None declared, C.H.M. van den Ende: None declared, Madelon Vonk Boehringer Ingelheim, GSK, Janssen, MSD, Novartis, Boehringer Ingelheim, Janssen, Unrestricted research grants from Boehringer Ingelheim, Ferrer and Galapagos.
Publisher
BMJ Publishing Group Ltd and European League Against Rheumatism,Elsevier B.V